Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof
AssigneeShanghai Micurx Pharmaceutical Co., Ltd.
InventorsHongyu YANG, Xinghai WANG
Life of this patent
Estimating the term…
Abstract
Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the conjugates in targeted treating of cancer.
Claims22
A ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises a structure of formula (IIa)
- wherein:
- Y and Z are independently selected from H halo, C1-C8 alkyl, and C1-C8 alkoxy;
- R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
- is
(canceled)
A compound of formula (Va), or a pharmaceutically acceptable salt or solvate thereof:
- wherein:
- Y and Z are independently selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
- R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
- is
- R1 and R2 are each hydrogen;
- n3 is 1;
- W is selected from the group consisting of C1-C8 alkylene, —(C1-C8 alkylene)-cycloalkylene-, arylene, heteroarylene, and linear heteroalkylene, wherein the linear heteroalkylene comprise 1 to 8 carbon atom(s), and 1 to 3 heteroatom(s) selected from the group consisting of N, O, S, SO, and SO2, and wherein the —(C1-C8 alkylene)-cycloalkylene-linear heteroalkylene, arylene, and heteroarylene are each independently optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
- L2 is the group consisting of —NR11(CH2CH2O)p1CH2CH2C(O)—, —NR11(CH2CH2O)p1CH2CH2—, —NR11(CH2CH2O)p1CH2C(O)—, —S(CH2)p1C(O)— and a chemical bond, wherein p1 is an integer selected from 1 to 20;
- wherein the left side of each of the L2 groups provided above is attached to L1;
- L3 is a peptide residue composed of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl;
- wherein the left side of each of the L3 groups provided above is attached to L2;
- L4 is selected from the group consisting of —NR12(CR13R14)t-, —C(O)NR12—, —C(O)NR12(CH)t—,
- and a chemical bond, wherein t is an integer selected from 1 to 6;
- wherein the left side of each of the L4 groups provided above is attached to the right side of L3 and the right side of each of the L4 groups is attached to X2;
- R10, R11 and R12 are each independently selected from the group consisting of H, allyl, haloalkyl, deuterated alkyl and hydroxyalkyl;
- R13 and R14 are each independently selected from the group consisting of H, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl;
- and
- R15 is selected from —CH2CH2SO2CH3, and —CH2CH2N(CH3)2.
A compound of formula (VIIa) or a pharmaceutically acceptable salt thereof:
- wherein:
- Y and Z are independently selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
- R3 is selected from H, halo, C1-C8 alkyl, and C1-C8 alkoxy;
- is
Dependencies are inferred from the claim text.